Paliperidon Teva (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidon Teva, is an antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is indicated for the treatment of schizophrenia in adults and for maintenance therapy to reduce relapse risk.

GNH USA supplies Paliperidon Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidon Teva is an antipsychotic that works within the schizophrenia treatment pathway. - Schizophrenia: helps control acute psychotic episodes and maintain symptom stability. - Schizoaffective disorder: reduces mood‑related psychotic symptoms when used as maintenance therapy. - Bipolar I disorder (maintenance): assists in preventing recurrence of manic or depressive episodes in patients already stabilized on other therapies.

Adverse reactions to paliperidone palmitate vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema - Headache - Drowsiness or somnolence - Weight gain - Restlessness or akathisia - Constipation

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe orthostatic hypotension - Hyperglycaemia or new‑onset diabetes - Seizures - Elevated prolactin with galactorrhoea or menstrual disturbances

When prescribing Paliperidon Teva, clinicians should consider several safety aspects. - Cardiovascular monitoring: patients with known cardiac disease or arrhythmias should be evaluated before use. - Metabolic assessment: monitor weight, glucose and lipid profiles regularly. - Movement disorders: watch for early signs of tardive dyskinesia or akathisia. - Pregnancy and lactation: avoid ; ;  - Renal function: dose adjustment may be needed for impaired renal clearance. - Store at room temperature: keep in the original packaging ; protect  ​​  "

Paliperidon Teva interacts  with     "  

Major   t   t \\